Analysts Set Immunocore Holdings plc (NASDAQ:IMCR) PT at $69.18

Shares of Immunocore Holdings plc (NASDAQ:IMCR) have been given an average recommendation of “Moderate Buy” by the thirteen research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $69.18.

IMCR has been the topic of a number of research reports. Mizuho cut shares of Immunocore from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $72.00 to $38.00 in a report on Monday, November 11th. HC Wainwright restated a “buy” rating and set a $100.00 price target on shares of Immunocore in a research report on Thursday, October 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Immunocore in a research report on Monday, September 9th. Guggenheim lowered shares of Immunocore from a “buy” rating to a “neutral” rating in a research report on Monday, October 7th. Finally, UBS Group started coverage on shares of Immunocore in a research report on Thursday, October 24th. They set a “sell” rating and a $24.00 price target for the company.

Hedge Funds Weigh In On Immunocore

A number of institutional investors and hedge funds have recently bought and sold shares of IMCR. Orion Portfolio Solutions LLC grew its position in Immunocore by 33.7% in the 1st quarter. Orion Portfolio Solutions LLC now owns 23,127 shares of the company’s stock valued at $1,503,000 after buying an additional 5,826 shares in the last quarter. Nan Fung Group Holdings Ltd bought a new position in shares of Immunocore during the 1st quarter valued at about $439,000. Janus Henderson Group PLC boosted its position in shares of Immunocore by 45.8% during the 1st quarter. Janus Henderson Group PLC now owns 257,080 shares of the company’s stock valued at $16,711,000 after purchasing an additional 80,748 shares in the last quarter. Tidal Investments LLC bought a new position in shares of Immunocore during the 1st quarter valued at about $423,000. Finally, DNB Asset Management AS boosted its position in shares of Immunocore by 35.0% during the 2nd quarter. DNB Asset Management AS now owns 7,211 shares of the company’s stock valued at $244,000 after purchasing an additional 1,868 shares in the last quarter. Institutional investors own 84.50% of the company’s stock.

Immunocore Stock Up 0.5 %

Shares of NASDAQ:IMCR opened at $32.28 on Friday. The stock has a market capitalization of $1.61 billion, a price-to-earnings ratio of -33.98 and a beta of 0.72. Immunocore has a 1-year low of $29.72 and a 1-year high of $76.98. The company’s fifty day moving average is $32.30 and its two-hundred day moving average is $37.69. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78.

Immunocore (NASDAQ:IMCR) last issued its earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.50. The company had revenue of $80.25 million for the quarter, compared to analysts’ expectations of $78.94 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The firm’s revenue was up 23.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.59) earnings per share. Equities analysts anticipate that Immunocore will post -0.94 EPS for the current year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.